Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
188 enrolled
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Phase 2 Recruiting
50 enrolled
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Phase 2 Recruiting
50 enrolled
Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
Phase 2 Recruiting
80 enrolled
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Phase 2 Recruiting
25 enrolled
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Phase 2 Recruiting
120 enrolled
MINT-2
Phase 2 Recruiting
142 enrolled
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Phase 2 Recruiting
44 enrolled
Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies
Phase 2 Recruiting
300 enrolled
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
Phase 2 Recruiting
119 enrolled
RAISE
Phase 2 Recruiting
13 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Phase 2 Recruiting
30 enrolled
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Phase 2 Recruiting
54 enrolled
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Phase 2 Recruiting
120 enrolled
Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Phase 2 Recruiting
53 enrolled
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Phase 2 Recruiting
37 enrolled
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Phase 2 Recruiting
150 enrolled
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
Phase 2 Recruiting
30 enrolled
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
92 enrolled
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Phase 2 Recruiting
156 enrolled
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Phase 2 Recruiting
30 enrolled
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 Recruiting
180 enrolled
LIGHT
Phase 2 Recruiting
55 enrolled
WOLF
Phase 2 Recruiting
87 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Phase 2 Recruiting
100 enrolled
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
40 enrolled
IDEAL
Phase 2 Recruiting
106 enrolled
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Phase 2 Recruiting
146 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2 Recruiting
39 enrolled
Light
Phase 2 Recruiting
26 enrolled
Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
Phase 2 Recruiting
35 enrolled
TSEMPRMSGC
Phase 2 Recruiting
90 enrolled
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Phase 2 Recruiting
30 enrolled
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Phase 2 Recruiting
70 enrolled
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Phase 2 Recruiting
32 enrolled
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Phase 2 Recruiting
32 enrolled
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Phase 2 Recruiting
45 enrolled
eVOLVE-02
Phase 2 Recruiting
257 enrolled
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Phase 2 Recruiting
189 enrolled
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
120 enrolled
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Phase 2 Recruiting
30 enrolled
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Phase 2 Recruiting
45 enrolled
POST-BIO
Phase 2 Recruiting
45 enrolled
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Phase 2 Recruiting
38 enrolled
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Phase 2 Recruiting
34 enrolled
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
Phase 2 Recruiting
243 enrolled
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
Phase 2 Recruiting
30 enrolled